Industry News
Pricing changes, regulatory decisions, coverage shifts and market exits — dated to the development, not to when we wrote it.
25 dated developments affecting what tirzepatide costs and who sells it. Most recent: Generic semaglutide launches abroad; US patients wait until 2031 (2026-08-06).
Every item names its source and closes on what it changes for someone paying for treatment. Where a story is still moving — a proposed rule, an ongoing enforcement matter — the item says so rather than implying it is settled.
All-in monthly cost at 10 mg
Every story, newest first
Generic semaglutide launches abroad; US patients wait until 2031
Indian generics started near $8 a month in March. The FDA has tentatively approved a US version that cannot le…
Lilly Q2: volume up 60%, realised prices down 13%
Zepbound revenue grew well below volume, which means the average price actually paid for branded tirzepatide i…
Medicare GLP-1 Bridge reported as an inflection point in month one
Access expanded to roughly 20 million eligible beneficiaries, with prior authorisation reportedly running smoo…
We re-checked sixteen compounded prices at source. Fifteen were wrong
Every correction moved the price upward, which means published cheapest figures are systematically low.…
Retatrutide reaches 30.3% weight loss in Phase 3
The triple agonist clears its pivotal obesity programme. Filing is planned for Q1 2027, which puts a prescript…
Three ownership structures, three risk profiles
Owned pharmacy, single contracted partner, or several named partners. The difference only becomes visible when…
Ro and WeightWatchers Clinic now carry brand only
Two of the largest consumer platforms stopped selling compounded tirzepatide during 2026, with membership bill…
Summer shipping is the season for cold-chain failures
Warm arrivals cluster in the hottest months, and most programmes put the judgement call on the patient.…
Microdose protocols spread, and they are not comparable to standard dosing
Fractional-dose plans at lower prices do not map onto the 2.5–15 mg ladder every comparison uses.…
FDA proposes excluding tirzepatide from the 503B bulks list
If finalised, outsourcing facilities would lose a pathway for compounding at scale.…
Membership stacking spreads: the advertised price is increasingly not the price
Several programmes now split the charge into medication plus a mandatory platform fee.…
More employers drop weight-management GLP-1 coverage at renewal
Withdrawals land mid-treatment, and interruption is the mechanism that undoes results.…
Alerts continue on counterfeit product and research-labelled peptide
Two different problems, one outcome: an unverified substance in a syringe.…
State action against a telehealth company's own compounding pharmacy
When the platform and the pharmacy are the same business, a regulatory action lands directly on patients with …
First-month promotional rates published as ongoing prices
A recurring error across round-ups, and the likely origin of several wrong figures.…
First oral GLP-1 for weight loss approved, priced from $149
A daily tablet reaches the market at a fraction of injectable brand pricing, with a smaller effect size.…
States gain the option to expand GLP-1 access through Medicaid
A route that did not exist for the lowest-income patients — but optional, so it will be a patchwork.…
Hims closes its compounded GLP-1 programme to new patients
Following a settlement with Novo Nordisk, one of the largest platforms exits compounded semaglutide.…
Zepbound KwikPen reaches self-pay pricing and retail pickup
The metered pen joins the vial at the same tiers, removing the syringe objection from the brand route.…
Lilly cuts Zepbound self-pay pricing to $299–$449
The starter dose drops to $299 and higher doses to $449, on a 45-day refill condition most coverage omits.…
FDA issues warning letters to compounded GLP-1 marketers
Several telehealth companies were cited over labelling and marketing claims, not over patient harm.…
Prepaid plans are where the money gets stuck
Multi-month discounts are real, and so is the fact that compounded medication is generally not refundable once…
A year after the shortage was declared over, the market has restructured
Scope narrowed and large platforms exited, but patient-specific compounding continues.…
Semaglutide approved for MASH with moderate to advanced fibrosis
The first GLP-1 with an FDA liver indication — and a coverage route that weight management is not.…
Zepbound approved for obstructive sleep apnoea
A discrete diagnosis with an approved indication is a stronger prior-authorisation argument than a BMI thresho…
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.